Tips and tricks in triple-negative breast cancer: How to manage patients in real-life practice?

ecancermedicalscience

Volumn 5, Issue 1, 2011, Pages

  Piccart, Martine ^a,b   Viale, G ^c,d   Ellis, P ^e,f   Abramowicz, M ^a,g   Carey, L ^h  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c UNIVERSITY OF MILAN   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e GUY S HOSPITAL   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g ERASME HOSPITAL   (Belgium)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR;

BREAST BIOPSY; BREAST CARCINOMA; CANCER GRADING; CANCER SURGERY; CARCINOMATOUS MASTITIS; CONFERENCE PAPER; FAMILY HISTORY; HUMAN; MEDICAL PRACTICE; MULTIPLE CYCLE TREATMENT; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 84856990379     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2011.217     Document Type: Conference Paper

References (34)

1. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) Arch Pathol Lab Med 134 e48-e72 PMID: 20586616
2. McCullough AE, Dell'Orto P, Reinholz MM et al (2010) Concordance of HER2 central assessment by two international central laboratories: a ring study within the framework of the adjuvant HER2-positive ALTTO trial (BIG2-06/N063D/EGF106708) Cancer Res 70 (Suppl) Abstract P3-10-36
3. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review Histopathology 52 108-118 PMID: 18171422 (Pubitemid 350265179)
4. Diaz LK, Cryns VL, Symmans WF, Sneige N (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice Adv Anat Pathol 14 419-430 PMID: 18049131 (Pubitemid 350307665)
5. Oakman C, Viale G, Di Leo A (2010) Management of triple negative breast cancer Breast 19 312-321 PMID: 20382530
6. American Cancer Society. Breast cancer. Available at: 〈http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf. pdf〉 (accesses June 2011).
7. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367-5374 PMID: 15328174 (Pubitemid 39100473)
8. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 2005 11 5678-5685 PMID: 16115903 (Pubitemid 41170290)
9. Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329-2334 PMID: 17438091 (Pubitemid 46698581)
10. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer J Clin Oncol 26 1275-1281 PMID: 18250347
11. Straver ME, Glas AM, Hannemann J et al (2010) The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer Breast Cancer Res Treat 119 551-558 PMID: 19214742
12. Conforti R, Boulet T, Tomasic G et al (2007) Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials Ann Oncol 18 1477-1483 PMID: 17515403 (Pubitemid 47365479)
13. Di Leo A, Isola J, Piette F et al (2008) A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy Poster presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, December 2008; Abstract 705
14. Cheang M, Chia SK, Tu D et al (2009) Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF J Clin Oncol 27 (Suppl) Abstract 519
15. Laporte S, Jones S, Chapelle C, Jacquin J, Martín M (2009) Consistency of effect of docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: meta-analysis of 12 randomized clinical trials Cancer Res 69 (Suppl 3) Abstract 605
16. Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 1496-1506 PMID: 17928597 (Pubitemid 47572635)
17. Gronwald J, Byrski T, Huzarski T et al (2009) Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients J Clin Oncol 27 (Suppl) Abstract 502
18. Ryan PD, Tung NM, Isakoff SJ et al (2007) Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy J Clin Oncol 27 (Suppl) Abstract 551
19. Leone JP, Guardiola V, Venkatraman A et al (2009) Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): retrospective analysis of 125 patients J Clin Oncol 27 (Suppl) Abstract 625
20. Sikov WM, Dizon DS, Strenger R et al (2009) Frequent pathologic complete response in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study J Clin Oncol 27 4693-4700 PMID: 19720916
21. Torrisi R, Balduzzi A, Ghisini R et al (2008) Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel Cancer Chemother Pharmacol 62 667-672 PMID: 18064460
22. Silver DP, Richardson AL, Eklund AC et al (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 28 1145-1153 PMID: 20100965
23. von Minckwitz G, Eidtmann H, Loibl S et al (2011) Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial Ann Oncol 22 301-306 PMID: 20624784
24. ClinicalTrials.gov (2010) BEATRICE study: a study of Avastin (bevacizumab) adjuvant therapy in triple negative breast cancer Available at: http://www.clinicaltrials.gov/show/NCT00528567 (accessed June 2011)
25. Wooster R, Weber BL (2003) Breast and ovarian cancer N Engl J Med 348 2339-2347 PMID: 12788999 (Pubitemid 36638109)
26. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 1401-1408 PMID: 9145676 (Pubitemid 27208598)
27. Mavaddat N, Pharoah PD, Blows F et al (2010) Familial relative risks for breast cancer by pathological subtype: a population-based cohort study Breast Cancer Res 12 R10 PMID: 20482762
28. American Society of Clinical Oncology (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility J Clin Oncol 21 2397-2406
29. Koshy N, Quispe D, Shi R, Mansour R, Burton GV (2010) Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients Breast 19 246-248 PMID: 20227277
30. Baselga J, Gomez P, Awada A et al (2010) The addition of cetuximab to cisplatin increases overall response rate and progression-free survival in metastatic triple-negative breast cancer: results of a randomized phase II study (BALI-1) Ann Oncol 21 (Suppl 8) Abstract 2740
31. Carey LA, O'Shaughnessy JA, Hoadley K et al (2009) Potential predictive markers of benefit from cetuximab in metastatic breast cancer: an analysis of two randomized phase 2 trials Cancer Res 69 (Suppl 3) Abstract 2014
32. O'Shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 205-214 PMID: 21208101
33. O'Shaughnessy J, Schwartzberg LS, Danso MA et al (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) J Clin Oncol 29 (Suppl) Abstract 1007
34. Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years Lancet 355 1822 (Pubitemid 30265099)